{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T13:41:55Z","timestamp":1769002915720,"version":"3.49.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000738","name":"US Department of Veterans Affairs","doi-asserted-by":"publisher","award":["IK2BX005303"],"award-info":[{"award-number":["IK2BX005303"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals USA Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.jtha.2024.02.017","type":"journal-article","created":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T00:17:05Z","timestamp":1709857025000},"page":"1605-1615","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Emicizumab promotes factor Xa generation on endothelial cells"],"prefix":"10.1016","volume":"22","author":[{"given":"Ammon M.","family":"Fager","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Ellsworth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nigel S.","family":"Key","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dougald M.","family":"Monroe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maureane","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2024.02.017_bib1","doi-asserted-by":"crossref","first-page":"540","DOI":"10.7326\/M19-1208","article-title":"Establishing the prevalence and prevalence at birth of hemophilia in males: a meta-analytic approach using national registries","volume":"171","author":"Iorio","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtha.2024.02.017_bib2","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0140-6736(11)61139-2","article-title":"Modern haemophilia care","volume":"379","author":"Berntorp","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2024.02.017_bib3","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1002\/ajh.23269","article-title":"Eradication of factor VIII inhibitors in patients with mild and moderate hemophilia A","volume":"87","author":"Kempton","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtha.2024.02.017_bib4","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1056\/NEJMoa1208024","article-title":"Factor VIII products and inhibitor development in severe hemophilia A","volume":"368","author":"Gouw","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.jtha.2024.02.017_bib5","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0268-960X(08)70001-8","article-title":"From theory to practice: applying current clinical knowledge and treatment strategies to the care of hemophilia a patients with inhibitors","volume":"22","author":"Gomperts","year":"2008","journal-title":"Blood Rev"},{"key":"10.1016\/j.jtha.2024.02.017_bib6","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1182\/blood-2006-04-017988","article-title":"A\u00a0randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study","volume":"109","author":"Astermark","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.02.017_bib7","first-page":"457","article-title":"Non-factor replacement therapy for haemophilia: a current update","volume":"16","author":"Franchini","year":"2018","journal-title":"Blood Transfus"},{"key":"10.1016\/j.jtha.2024.02.017_bib8","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/bjh.18379","article-title":"Current and future therapies for haemophilia\u2013beyond factor replacement therapies","volume":"200","author":"Nogami","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2024.02.017_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0057479","article-title":"Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity","volume":"8","author":"Sampei","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jtha.2024.02.017_bib10","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/nm.2942","article-title":"A\u00a0bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model","volume":"18","author":"Kitazawa","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.jtha.2024.02.017_bib11","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1182\/blood-2017-08-801662","article-title":"Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?","volume":"130","author":"Lenting","year":"2017","journal-title":"Blood"},{"issue":"Suppl 6","key":"10.1016\/j.jtha.2024.02.017_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH Guidelines for the Management of Hemophilia panelists and co-authors. WFH guidelines for the management of hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.02.017_bib13","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.02.017_bib14","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.jtha.2023.01.010","article-title":"Hemorrhagic and thrombotic adverse events associated with emicizumab and extended half-life factor VIII replacement drugs: EudraVigilance data of 2021","volume":"21","author":"Abbattista","year":"2023","journal-title":"J\u00a0Thromb Haemost"},{"issue":"Suppl 1","key":"10.1016\/j.jtha.2024.02.017_bib15","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/jth.15186","article-title":"Establishment of a framework for assessing mortality in persons with congenital hemophilia A and its application to an adverse event reporting database","volume":"19","author":"Pipe","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.02.017_bib16","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have hemophilia A without inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.02.017_bib17","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1016\/S2352-3026(19)30054-7","article-title":"Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study","volume":"6","author":"Pipe","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtha.2024.02.017_bib18","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood.2019001869","article-title":"A\u00a0multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors","volume":"134","author":"Young","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.02.017_bib19","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1111\/jth.14430","article-title":"Intrinsic differences between FVIIIa mimetic bispecific antibodies and FVIII prevent assignment of FVIII-equivalence","volume":"17","author":"Leksa","year":"2019","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.02.017_bib20","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1126\/science.1084183","article-title":"Modulation of alpha-thrombin function by distinct interactions with platelet glycoprotein Ibalpha","volume":"301","author":"Celikel","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.jtha.2024.02.017_bib21","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1042\/bj3100539","article-title":"Binding of blood coagulation factor VIII and its light chain to phosphatidylserine\/phosphatidylcholine bilayers as measured by ellipsometry","volume":"310","author":"Spaargaren","year":"1995","journal-title":"Biochem J"},{"key":"10.1016\/j.jtha.2024.02.017_bib22","doi-asserted-by":"crossref","first-page":"16467","DOI":"10.1016\/S0021-9258(18)37615-4","article-title":"The binding of 35S-labeled recombinant factor VIII to activated and unactivated human platelets","volume":"263","author":"Nesheim","year":"1988","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jtha.2024.02.017_bib23","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1182\/blood-2015-01-620245","article-title":"Platelet binding sites for factor VIII in relation to fibrin and phosphatidylserine","volume":"126","author":"Gilbert","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.02.017_bib24","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.trsl.2016.03.008","article-title":"Sickle cell disease biochip: a functional red blood cell adhesion assay for monitoring sickle cell disease","volume":"173","author":"Alapan","year":"2016","journal-title":"Transl Res"},{"key":"10.1016\/j.jtha.2024.02.017_bib25","first-page":"585","article-title":"von Willebrand factor as a regulator of intrinsic factor X activation","volume":"123","author":"Koppelman","year":"1994","journal-title":"J\u00a0Lab Clin Med"},{"key":"10.1016\/j.jtha.2024.02.017_bib26","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/j.1365-2141.1994.tb04918.x","article-title":"The activation of human blood coagulation factor X on the surface of endothelial cells: a comparison with various vascular cells, platelets and monocytes","volume":"87","author":"Brinkman","year":"1994","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2024.02.017_bib27","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1161\/hq0302.105359","article-title":"Phospholipid-binding domain of factor VIII is involved in endothelial cell-mediated activation of factor X by factor IXa","volume":"22","author":"Brinkman","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jtha.2024.02.017_bib28","doi-asserted-by":"crossref","first-page":"6717","DOI":"10.1016\/S0021-9258(18)88838-X","article-title":"The binding of factor IXa to cultured bovine aortic endothelial cells. Induction of a specific site in the presence of factors VIII and X","volume":"260","author":"Stern","year":"1985","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jtha.2024.02.017_bib29","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1055\/s-0040-1717114","article-title":"Pharmacokinetics and pharmacodynamics of emicizumab in persons with hemophilia A with factor VIII inhibitors: HAVEN 1 study","volume":"121","author":"Schmitt","year":"2021","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.02.017_bib30","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1111\/jth.14203","article-title":"In vitro studies show synergistic effects of a procoagulant bispecific antibody and bypassing agents","volume":"16","author":"Hartmann","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.02.017_bib31","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/hae.14213","article-title":"Comparison of bypassing agents in patients on emicizumab using global hemostasis assays","volume":"27","author":"Kizilocak","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.02.017_bib32","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12561","article-title":"The effect of emicizumab and bypassing agents in patients with hemophilia - an in\u00a0vitro study","volume":"5","author":"Schultz","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.02.017_bib33","doi-asserted-by":"crossref","first-page":"e181","DOI":"10.3324\/haematol.2017.185330","article-title":"Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab","volume":"103","author":"Dargaud","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2024.02.017_bib34","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.nec.2018.05.001","article-title":"Biology of coagulation and coagulopathy in neurologic surgery","volume":"29","author":"Fager","year":"2018","journal-title":"Neurosurg Clin N Am"},{"issue":"Suppl 1","key":"10.1016\/j.jtha.2024.02.017_bib35","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1538-7836.2007.02515.x","article-title":"Vascular bed-specific thrombosis","volume":"5","author":"Aird","year":"2007","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.02.017_bib36","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1538-7836.2008.02873.x","article-title":"Tissue-specific hemostasis: role of tissue factor","volume":"6","author":"Mackman","year":"2008","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.02.017_bib37","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/jth.12452","article-title":"Measurement of factor IX activity in plasma-derived and recombinant concentrates: insights from thrombin generation and activation-based assays","volume":"12","author":"Yu","year":"2014","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.02.017_bib38","first-page":"155","article-title":"Factor VII and activated-factor-VII content of prothrombin complex concentrates. The PCC Study Group","volume":"73","author":"Hellstern","year":"1997","journal-title":"Vox Sang"},{"key":"10.1016\/j.jtha.2024.02.017_bib39","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/hae.12873","article-title":"Pro- and anticoagulant factors facilitate thrombin generation and balance the haemostatic response to FEIBA\u00ae in prophylactic therapy","volume":"22","author":"Varadi","year":"2016","journal-title":"Haemophilia"},{"issue":"Suppl 2","key":"10.1016\/j.jtha.2024.02.017_bib40","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2516.2004.00934.x","article-title":"FEIBA: mode of action","volume":"10","author":"Turecek","year":"2004","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.02.017_bib41","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/hae.14684","article-title":"Safety of FEIBA and emicizumab (SAFE): dose escalation study evaluating the safety of in\u00a0vivo administration of activated prothrombin complex concentrate in haemophilia A patients on emicizumab","volume":"29","author":"Kizilocak","year":"2023","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.02.017_bib42","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1161\/01.CIR.0000080882.35274.AD","article-title":"Effect of endothelial shear stress on the progression of coronary artery disease, vascular remodeling, and in-stent restenosis in humans: in\u00a0vivo 6-month follow-up study","volume":"108","author":"Stone","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2024.02.017_bib43","doi-asserted-by":"crossref","first-page":"5489","DOI":"10.1172\/JCI124791","article-title":"Hemodynamic regulation of perivalvular endothelial gene expression prevents deep venous thrombosis","volume":"129","author":"Welsh","year":"2019","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jtha.2024.02.017_bib44","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00281-011-0285-5","article-title":"Endothelium--role in regulation of coagulation and inflammation","volume":"34","author":"van Hinsbergh","year":"2012","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.jtha.2024.02.017_bib45","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1182\/blood.V84.7.2206.2206","article-title":"Effect of blood flow on thrombin generation is dependent on the nature of the thrombogenic surface","volume":"84","author":"Diqu\u00e9lou","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.02.017_bib46","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1752-0509-4-5","article-title":"Blood flow controls coagulation onset via the positive feedback of factor VII activation by factor Xa","volume":"4","author":"Shibeko","year":"2010","journal-title":"BMC Syst Biol"},{"key":"10.1016\/j.jtha.2024.02.017_bib47","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1007\/s10439-015-1346-z","article-title":"Altered flow changes thrombin generation rate of circulating platelets","volume":"43","author":"Yin","year":"2015","journal-title":"Ann Biomed Eng"},{"key":"10.1016\/j.jtha.2024.02.017_bib48","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1172\/JCI119604","article-title":"Replacing the first epidermal growth factor-like domain of factor IX with that of factor VII enhances activity in\u00a0vitro and in canine hemophilia B","volume":"100","author":"Chang","year":"1997","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jtha.2024.02.017_bib49","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1161\/ATVBAHA.110.216531","article-title":"Properties of procoagulant platelets: defining and characterizing the subpopulation binding a functional prothrombinase","volume":"30","author":"Fager","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jtha.2024.02.017_bib50","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1161\/01.ATV.0000155987.26583.9b","article-title":"Platelet heterogeneity: variation in coagulation complexes on platelet subpopulations","volume":"25","author":"Kempton","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jtha.2024.02.017_bib51","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/0006-291X(83)90365-0","article-title":"Binding of coagulation factors IX and X to the endothelial cell surface","volume":"111","author":"Heimark","year":"1983","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jtha.2024.02.017_bib52","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1073\/pnas.80.13.4119","article-title":"Binding of factors IX and IXa to cultured vascular endothelial cells","volume":"80","author":"Stern","year":"1983","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtha.2024.02.017_bib53","doi-asserted-by":"crossref","first-page":"11068","DOI":"10.1073\/pnas.93.20.11068","article-title":"Identification of the endothelial cell binding site for factor IX","volume":"93","author":"Cheung","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtha.2024.02.017_bib54","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1021\/bi00121a031","article-title":"The endothelial cell binding determinant of human factor IX resides in the gamma-carboxyglutamic acid domain","volume":"31","author":"Toomey","year":"1992","journal-title":"Biochemistry"},{"key":"10.1016\/j.jtha.2024.02.017_bib55","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1016\/S0021-9258(18)52265-1","article-title":"The gamma-carboxyglutamic acid and epidermal growth factor-like domains of factor X. Effect of isolated domains on prothrombin activation and endothelial cell binding of factor X","volume":"266","author":"Persson","year":"1991","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jtha.2024.02.017_bib56","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1182\/blood.V100.1.153","article-title":"Circulating and binding characteristics of wild-type factor\u00a0IX and certain Gla domain mutants in\u00a0vivo","volume":"100","author":"Gui","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.02.017_bib57","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1042\/bj2230599","article-title":"Binding of human blood-coagulation factors IXa and X to phospholipid membranes","volume":"223","author":"Mertens","year":"1984","journal-title":"Biochem J"},{"key":"10.1016\/j.jtha.2024.02.017_bib58","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jtha.2023.09.017","article-title":"Thrombin generation on vascular cells in the presence of factor VIII and\/or emicizumab","volume":"22","author":"Atsou","year":"2024","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.02.017_bib59","first-page":"758","article-title":"Is endothelial activation a critical event in thrombotic thrombocytopenic purpura?","volume":"12","author":"Cauchois","year":"2023","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.jtha.2024.02.017_bib60","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1046\/j.1365-2141.2001.02516.x","article-title":"Elevated endothelial microparticles in thrombotic thrombocytopenic purpura: findings from brain and renal microvascular cell culture and patients with active disease","volume":"112","author":"Jimenez","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2024.02.017_bib61","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1182\/blood-2014-03-565010","article-title":"New insights into the spatiotemporal localization of prothrombinase in\u00a0vivo","volume":"124","author":"Ivanciu","year":"2014","journal-title":"Blood"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624001211?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624001211?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T21:10:14Z","timestamp":1762549814000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783624001211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":61,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S1538783624001211"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2024.02.017","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emicizumab promotes factor Xa generation on endothelial cells","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2024.02.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}